TYK2 and systemic lupus erythematosus: Additional complexity arises from the variable clinical expression of lupus (skin-limited SCLE/DLE versus multi-organ SLE), the spectrum of ANA/ENA serologies, and the expanding use of newer agents such as IL-23 and TYK2 inhibitors in routine psoriasis care [12,13,14,35,36,37].